Medications for alcohol use disorder: what they do

Medications for alcohol use disorder can support a change in drinking alongside medical follow-up, therapy, peer support, or a wider recovery plan. They are still underused, even though several options have evidence from randomized trials.

The main approved options in many countries are naltrexone, acamprosate, and disulfiram. They work differently and suit different goals and medical circumstances. Their availability and labeling vary by location.

This guide covers medication for ongoing alcohol use disorder. Possible alcohol withdrawal requires a separate safety assessment. If you drink heavily or regularly, have had withdrawal symptoms, or use alcohol to steady yourself, review the alcohol safety guide before abruptly stopping.

What the evidence shows overall

A 2023 systematic review for the Agency for Healthcare Research and Quality included 118 studies. It found moderate-strength evidence that oral naltrexone reduced return to any drinking, return to heavy drinking, drinking days, and heavy-drinking days. Acamprosate had moderate-strength evidence for reducing return to any drinking. Most studies provided counselling in both medication and comparison groups, so the findings reflect medication added to behavioral care (McPheeters et al., 2023).

A related JAMA meta-analysis included 118 trials with 20,976 participants and concluded that oral naltrexone and acamprosate had the strongest evidence among commonly used medications when combined with psychosocial interventions (McPheeters et al., 2023).

Average study results cannot choose a medicine for one person. The prescribing decision also involves the outcome you want, previous response, health conditions, current medicines, follow-up access, and whether the treatment can be taken consistently.

Naltrexone

Naltrexone blocks opioid receptors involved in alcohol reward and reinforcement. It is available as an oral medicine and, in some countries, a long-acting injection.

Trials commonly measure return to heavy drinking, number of drinking days, and abstinence. The 2023 AHRQ review found moderate-strength evidence for several oral-naltrexone drinking outcomes. Evidence for injectable naltrexone supported fewer drinking days and heavy-drinking days with lower certainty (McPheeters et al., 2023).

Naltrexone also blocks opioid medicines. Starting it while opioids remain in the body can precipitate withdrawal, and it affects future opioid pain treatment. Tell the prescriber about prescribed pain medicines, cough or diarrhea products, opioid-use treatment, and any non-prescribed opioid exposure. Liver health and the product's current labeling also require review.

Questions to ask include:

• Which outcome are we targeting with naltrexone?
• Do any of my medicines contain an opioid?
• How would pain be managed during treatment?
• Which liver tests or symptoms require follow-up?
• Is oral or injectable treatment available and covered here?

Acamprosate

Acamprosate is used to support the maintenance of abstinence after alcohol has stopped. Its exact clinical mechanism remains incompletely understood, with research focusing on brain signaling altered by chronic alcohol exposure.

The 2023 AHRQ review found moderate-strength evidence that acamprosate reduced return to any drinking. It did not show the same pattern as naltrexone across heavy-drinking outcomes (McPheeters et al., 2023). This makes the treatment goal relevant to the comparison.

Kidney function matters when assessing acamprosate. The medicine also has a greater daily pill burden than some alternatives, which can affect whether the plan is workable. Ask when treatment would start, how kidney health changes eligibility, what to do after a missed dose, and how progress will be evaluated.

Disulfiram

Disulfiram interferes with alcohol metabolism. Drinking alcohol while taking it can cause a severe unpleasant reaction. The purpose is to create a strong external barrier around a planned period of abstinence.

Evidence is difficult to interpret because taking the medicine consistently and knowing whether treatment is supervised can strongly affect results. A 2022 network meta-analysis found evidence for improved abstinence with disulfiram, while also noting the broader limitations and adverse-effect differences across medication trials (Bahji et al., 2022).

Disulfiram requires careful education about alcohol exposure, contraindications, interactions, and urgent symptoms. Products containing alcohol can matter depending on the route and amount of exposure. A prescriber or pharmacist should explain the actual precautions for the locally available product.

This option may appeal to someone who wants a visible commitment device and has reliable follow-up. It can be a poor fit when treatment is coerced, adherence is unlikely, the person plans to drink, or medical factors make the reaction unsafe.

Other medications used off-label

Some clinicians consider medicines that lack a specific alcohol-use-disorder approval in their country. Topiramate and gabapentin are among the most studied.

The AHRQ review found moderate-strength evidence that topiramate improved several drinking outcomes, along with a less favorable side-effect profile. Evidence for gabapentin was lower and less consistent (McPheeters et al., 2023). Off-label use requires the same careful review of goals, evidence, unwanted effects, interactions, pregnancy, and monitoring.

An online list cannot establish that an off-label option fits your case. Ask why it is being considered, which outcome it targets, how strong the evidence is, and how the plan will be stopped or changed if benefits do not appear.

Medication and your drinking goal

Treatment goals may include abstinence, avoiding heavy-drinking days, reducing drinking, or stabilizing enough to engage with further care. Medication studies use different outcomes, so a result on one outcome should not be presented as success on all of them.

Write down the result you and the prescriber will evaluate. Examples include:

• no alcohol use during a defined period
• fewer heavy-drinking days
• fewer drinking days overall
• reduced intensity when drinking occurs
• better attendance at therapy or medical follow-up
• fewer alcohol-related consequences

The goal can change after review. A clear measure makes the conversation more useful than a general question about whether the medicine is "working."

Information to bring to a prescriber

Prepare:

• a recent record of drinking days, amounts, and heavy-drinking episodes
• the date and pattern of any recent withdrawal symptoms
• every prescription, over-the-counter medicine, and supplement
• any opioid use or possible need for opioid pain treatment
• liver, kidney, seizure, pregnancy, and mental-health history
• earlier alcohol medications and what happened
• your preferred goal and concerns about cost, privacy, or adherence

The doctor conversation guide turns this list into a short appointment plan.

What medication cannot do alone

Medication does not remove alcohol from the environment, arrange transport from a difficult event, repair a relationship, or practice a response to a recurring drinking situation. Those parts of recovery need their own plan.

Behavioral care can support medication adherence and address patterns that remain after the pharmacological effect. The therapy for alcohol use disorder guide explains the main psychological approaches. Peer-support meetings can add regular contact between clinical appointments.

Continuing care matters because alcohol-use patterns and treatment needs can change. A systematic review of continuing-care interventions found some evidence that active follow-up added to usual care can improve outcomes, although the studies were heterogeneous and only a small number were methodologically strong (Lenaerts et al., 2014).

Monitor benefits, unwanted effects, and fit

Agree on when the first review will happen and what would trigger earlier contact. Keep a brief record of drinking, cravings, missed doses, unwanted effects, and changes in mood or health.

Seek urgent help for severe or rapidly worsening symptoms, a serious reaction, thoughts of self-harm, or another emergency. For ordinary concerns, contact the prescriber or pharmacist before changing the regimen.

Medication decisions can be revised. A treatment can be evidence-based and still fit one person's circumstances poorly. The review process exists to compare benefit, burden, safety, and the next available option.